Immunogenicity of biopharmaceuticals

Area of Science:

• Biopharmaceutical science
• Immunology
• Drug development

Background:

• Biopharmaceutical availability has increased, with biosimilars emerging as patents expire.
• Immunogenicity is a primary safety concern for biopharmaceuticals and biosimilars.
• Factors influencing immunogenicity are not fully understood, and severe reactions like pure red cell aplasia have been observed.

Purpose of the Study:

• To highlight the safety concerns of biosimilar agents, particularly immunogenicity.
• To discuss the limitations of current laboratory methods in predicting clinical properties and bioequivalence.
• To emphasize the challenges in comparing biosimilar studies due to variability and lack of standardization.

Main Methods:

• Review of existing literature on biopharmaceuticals, biosimilars, and immunogenicity.
• Analysis of documented cases and factors influencing immune responses.
• Evaluation of current laboratory measurement methods and their limitations.

Main Results:

• Immunogenicity remains a significant safety concern for biopharmaceuticals and biosimilars.
• Product- and host-related factors impact immune response, but many remain unknown.
• Existing laboratory methods are inadequate for predicting clinical outcomes or bioequivalence, hindering reliable comparisons.

Conclusions:

• The emergence of biosimilars necessitates a thorough understanding of immunogenicity risks.
• Standardization of laboratory methods and data presentation is crucial for reliable biosimilar evaluation.
• Further research is needed to elucidate unknown factors affecting immunogenicity and ensure biosimilar safety.